DNA Ploidy as a Significant Predictor of Recurrence‐Free Survival in Male Patients with Breast Cancer

Sridhar Mani, Bruce G. Haffty, John Sinard, Diana Fischer, Rose J. Papac, Stuart Flynn

Research output: Contribution to journalArticlepeer-review


Abstract: DNA flow cytometry has been extensively studied in female breast carcinoma. However, there is limited data evaluating DNA ploidy in male breast cancer. In order to further assess the prognostic significance of DNA ploidy in male breast carcinoma, we retrospectively reviewed 55 cases (52 patients) of histologically proven male breast carcinoma treated at our institution from January 1971 through January 1992. Of the 55 cases, 32 paraffin‐embedded blocks were available for DNA flow cytometry analysis. As of June 1993, median follow‐up is 7.0 years. In the overall population of 55 cases, univariate analysis identified TNM stage, tumor size, and nodal status as significant prognostic indicators of overall survival and disease‐free survival. In the 32 cases available for DNA flow cytometry, both local recurrences and distant metastases were more frequent in the aneuploid population. Univariate analysis revealed DNA ploidy to be a significant prognostic factor for local recurrence‐free survival and distant metastasis‐free survival. DNA ploidy correlated significantly with stage at diagnosis (p =.04), tumor size (p =.04) and nodal status (p =.02). In a multivariate analysis of 26 patients on whom all data were available (DNA ploidy, tumor size, clinical stage and nodal status), DNA ploidy was an independent predictor of disease‐free survival (p =.05). In this retrospective analysis, we conclude that DNA ploidy has prognostic significance in male breast carcinoma.

Original languageEnglish (US)
Pages (from-to)356-361
Number of pages6
JournalThe Breast Journal
Issue number6
StatePublished - Nov 1995
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology


Dive into the research topics of 'DNA Ploidy as a Significant Predictor of Recurrence‐Free Survival in Male Patients with Breast Cancer'. Together they form a unique fingerprint.

Cite this